Table 4 GVHD-related outcomes Endpoint .... | American Society of Hematology

Table 4

GVHD-related outcomes

Endpoint	MMF		Placebo		HR (95% CI)*	P
Endpoint	No. of events	Cumulative incidence at 2 y	No. of events	Cumulative incidence at 2 y	HR (95% CI)*	P
Treatment success	11	0.23	13	0.18	1.66 (0.7-3.7)	.22
Treatment failure	43	0.70	38	0.64	1.65 (1.1-2.6)	.03
Secondary systemic treatment†	24	0.38	25	0.44	1.19 (0.7-2.1)	.55
Bronchiolitis obliterans†	5	0.09	4	0.07	1.61 (0.4-6.0)	.48
Withdrawal of prednisone†	30	0.44	33	0.41	1.28 (0.8-2.1)	.34
End of systemic treatment†	15	0.23	15	0.18	1.51 (0.7-3.2)	.28

Endpoint	MMF		Placebo		HR (95% CI)*	P
Endpoint	No. of events	Cumulative incidence at 2 y	No. of events	Cumulative incidence at 2 y	HR (95% CI)*	P
Treatment success	11	0.23	13	0.18	1.66 (0.7-3.7)	.22
Treatment failure	43	0.70	38	0.64	1.65 (1.1-2.6)	.03
Secondary systemic treatment†	24	0.38	25	0.44	1.19 (0.7-2.1)	.55
Bronchiolitis obliterans†	5	0.09	4	0.07	1.61 (0.4-6.0)	.48
Withdrawal of prednisone†	30	0.44	33	0.41	1.28 (0.8-2.1)	.34
End of systemic treatment†	15	0.23	15	0.18	1.51 (0.7-3.2)	.28

Hazard ratio for MMF arm relative to placebo arm; stratified on the number of sites affected by chronic GVHD at onset (1 vs > 1) and the type of conditioning regimen (myeloablative vs nonmyeloablative).

†

Competing risks are limited to recurrent malignancy and death.

View Large

This Feature Is Available To Subscribers Only